New York, USA, July 27, 2023 (GLOBE NEWSWIRE) -- Non-small Cell Lung Cancer Market is Projected to Boost by 2032, Predicts DelveInsight | Key Companies Working in Space - AstraZeneca, BMS, AbbVie, Roche, Merck, Novartis, Pfizer, Takeda, Eli Lilly, Immutep, Sanofi, GlaxoSmithKline
The growth of the non-small cell lung cancer market is expected to be driven by increasing incident cases of NSCLC, continued uptake of approved therapies mainly immune checkpoint inhibitors, expected entry of potential premium price emerging therapies, and increasing awareness of mutations, among others.
DelveInsight’s Non-small Cell Lung Cancer Market Insights report includes a comprehensive understanding of current treatment practices, non-small cell lung cancer emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].
Key Takeaways from the Non-small Cell Lung Cancer Market Report
- As per DelveInsight’s analysis, the non-small cell lung cancer market is anticipated to grow at a significant CAGR by 2032.
- According to the assessment done by DelveInsight, the United States had 227K incident cases of lung cancer in 2020, of which ~85%, i.e., 193K were NSCLC cancer patients.
- Leading non-small cell lung cancer companies such as EMD Serono, Merck, Cellular Biomedicine Group, Inc., Celgene, CellSight Technologies, Inc., BeyondSpring Pharmaceuticals Inc., J Ints Bio, Forward Pharmaceuticals Co., Ltd., AstraZeneca, Bristol-Myers Squibb, Teligene US, Rain Oncology Inc, ReHeva Biosciences, Inc., Amgen, Novartis, RedCloud Bio, Parexel, Vitrac Therapeutics, LLC, Mythic Therapeutics, Instil Bio, Mirati Therapeutics Inc., Daiichi Sankyo, Inc., AstraZeneca, Precision Biologics, Inc, Promontory Therapeutics Inc., Palobiofarma SL, Regeneron Pharmaceuticals, Revolution Medicines, Inc., Cullinan Oncology, LLC, Iovance Biotherapeutics, Inc., Innate Pharma, and others are developing novel non-small cell lung cancer drugs that can be available in the non-small cell lung cancer market in the coming years.
- Some of the key therapies for non-small cell lung cancer treatment include M1774, C-TIL051, ACY-241 + Nivolumab, 18F-AraG, Nivolumab + Plinabulin, JIN-A02, FWD1509 MsOH, Osimertinib, BMS-813160, Sutetinib Maleate Capsule, Sotorasib and Tarloxotinib, RH324, AMG 794, Capmatinib, H002, VIC-1911, MYTX-011, ITIL-306, Adagrasib, DS-1062a, NEO-201 in combination with pembrolizumab, PT-112, PBF-1129, REGN2810, RMC-4630, CLN-081, LN-145, IPH5201 + durvalumab + standard chemotherapy, and others.
Discover which therapies are expected to grab the major non-small cell lung cancer market share @ Non-small Cell Lung Cancer Market Report
Non-small Cell Lung Cancer Overview
Non-small cell lung cancer (NSCLC) is one of the most prevalent types of lung cancer, accounting for approximately 85% of all lung cancer cases. This malignancy originates in the tissues of the lungs and can spread to other parts of the body if not diagnosed and treated promptly. The primary causes of NSCLC are often related to long-term exposure to harmful substances, particularly cigarette smoking. It is well-established that smokers have a significantly higher risk of developing this form of lung cancer compared to non-smokers.
The symptoms of NSCLC can be subtle in the early stages, making it challenging to detect. Persistent cough, chest pain, shortness of breath, unexplained weight loss, and coughing up blood are some common indicators of the disease. In advanced stages, individuals may experience fatigue, bone pain, and difficulty swallowing, as the cancer spreads to other organs. Diagnosing NSCLC typically involves a combination of imaging tests, such as chest X-rays, CT scans, and PET scans, which help visualize the tumor and its extent. Tissue samples, obtained through procedures like bronchoscopy or biopsy, are examined under a microscope to confirm the presence of cancer cells and determine the specific type and stage of NSCLC.
Non-small Cell Lung Cancer Epidemiology Segmentation
The non-small cell lung cancer epidemiology section provides insights into the historical and current non-small cell lung cancer patient pool and forecasted trends for the seven individual major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders.
The non-small cell lung cancer market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
- Total Incident Cases of NSCLC Patients
- Total Incident Cases of NSCLC Patients by Histology
- Total Diagnosed Cases of NSCLC Patients by Stages
- Total NSCLC Cases of Patients by Genetic Mutation/Biomarkers
- Total Treated Cases of NSCLC Patients by Line of Therapies
Download the report to understand which factors are driving non-small cell lung cancer epidemiology trends @ Non-small Cell Lung Cancer Epidemiological Insights
Non-small Cell Lung Cancer Treatment Market
The treatment of NSCLC involves a multidisciplinary approach tailored to each patient’s specific condition and stage of the disease. Several NSCLC treatment options are available, depending on factors such as tumor size, location, overall health, and the presence of specific genetic mutations. Surgery is often the primary treatment for early-stage NSCLC, aiming to remove the tumor and surrounding tissues. For more advanced cases or when surgery is not feasible, other treatments come into play. These may include radiation therapy, which uses high-energy beams to target and destroy cancer cells, and chemotherapy, where powerful drugs are used to kill cancer cells or slow their growth.
In recent years, targeted therapies and immunotherapy have revolutionized the treatment of NSCLC. Targeted therapies focus on specific genetic mutations present in the cancer cells, disrupting their growth signals and hindering tumor development. On the other hand, immunotherapy harnesses the body’s immune system to recognize and attack cancer cells effectively.
Often, a combination of treatments may be used to achieve the best results, such as combining chemotherapy with immunotherapy or targeted therapy. The choice of NSCLC treatment is a complex decision made by a team of medical professionals, including oncologists, surgeons, and radiation specialists, in consultation with the patient. Research and advancements in NSCLC treatment continue to evolve, providing hope for improved outcomes and better quality of life for individuals battling this challenging disease. Regular follow-up and close monitoring are crucial for evaluating the treatment’s effectiveness and managing any potential side effects.
To know more about non-small cell lung cancer treatment, visit @ Non-small Cell Lung Cancer Treatment Drugs
Key Non-small Cell Lung Cancer Therapies and Companies
- M1774: EMD Serono/Merck
- C-TIL051: Cellular Biomedicine Group, Inc.
- ACY-241 + Nivolumab: Celgene
- 18F-AraG: CellSight Technologies, Inc.
- Nivolumab + Plinabulin: BeyondSpring Pharmaceuticals Inc.
- JIN-A02: J Ints Bio
- FWD1509 MsOH: Forward Pharmaceuticals Co., Ltd.
- Osimertinib: AstraZeneca
- BMS-813160: Bristol-Myers Squibb
- Sutetinib Maleate Capsule: Teligene US
- Sotorasib and Tarloxotinib: Rain Oncology Inc
- RH324: ReHeva Biosciences, Inc.
- AMG 794: Amgen
- Capmatinib: Novartis
- H002: RedCloud Bio/Parexel
- VIC-1911: Vitrac Therapeutics, LLC
- MYTX-011: Mythic Therapeutics
- ITIL-306: Instil Bio
- Adagrasib: Mirati Therapeutics Inc.
- DS-1062a: Daiichi Sankyo, Inc./AstraZeneca
- NEO-201 in combination with pembrolizumab: Precision Biologics, Inc
- PT-112: Promontory Therapeutics Inc.
- PBF-1129: Palobiofarma SL
- REGN2810: Regeneron Pharmaceuticals
- RMC-4630: Revolution Medicines, Inc.
- CLN-081: Cullinan Oncology, LLC
- LN-145: Iovance Biotherapeutics, Inc.
- IPH5201 + durvalumab + standard chemotherapy: Innate Pharma
Learn more about the FDA-approved drugs for non-small cell lung cancer @ Drugs for Non-small Cell Lung Cancer Treatment
Non-small Cell Lung Cancer Market Dynamics
Non-small cell lung cancer market dynamics have undergone significant changes in recent years. As one of the most prevalent types of lung cancer, the NSCLC market has been driven by several key factors. Technological advancements in diagnostic tools, such as next-generation sequencing and liquid biopsies, have improved early detection rates, leading to better patient outcomes. Additionally, the emergence of targeted therapies and immunotherapies has revolutionized treatment options, offering more personalized and effective approaches.
The competitive landscape has also witnessed intense activity, with pharmaceutical companies continuously developing and launching innovative drugs. As a result, the NSCLC market has become highly competitive, prompting pricing pressures and cost-containment efforts from payers and healthcare systems. Alongside this, regulatory changes and evolving reimbursement policies have shaped the access and affordability of NSCLC treatments.
Moreover, patient advocacy groups and increased awareness campaigns have played a pivotal role in driving research funding and shaping healthcare policies, further impacting the NSCLC market. Collaboration between industry stakeholders, academia, and government bodies has accelerated the pace of research and development in this area.
In the dynamic landscape of the NSCLC market, several barriers have emerged, hindering the smooth progression of research, development, and access to effective treatments. Advanced therapies, such as targeted therapies and immunotherapies, often come with a high price tag. The cost of these treatments can pose a significant financial burden on patients and healthcare systems, leading to limited access, especially in regions with constrained healthcare budgets.
Moreover, the process of gaining regulatory approvals for new drugs is lengthy and complex. Stringent requirements and clinical trial standards often lead to delays and substantial financial investments for pharmaceutical companies. This can slow down the introduction of innovative therapies into the NSCLC market.
| Non-small Cell Lung Cancer Report Metrics | Details |
| Study Period | 2019–2032 |
| Non-small Cell Lung Cancer Report Coverage | 7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan] |
| Key Non-small Cell Lung Cancer Companies | EMD Serono, Merck, Cellular Biomedicine Group, Inc., Celgene, CellSight Technologies, Inc., BeyondSpring Pharmaceuticals Inc., J Ints Bio, Forward Pharmaceuticals Co., Ltd., AstraZeneca, Bristol-Myers Squibb, Teligene US, Rain Oncology Inc, ReHeva Biosciences, Inc., Amgen, Novartis, RedCloud Bio, Parexel, Vitrac Therapeutics, LLC, Mythic Therapeutics, Instil Bio, Mirati Therapeutics Inc., Daiichi Sankyo, Inc., AstraZeneca, Precision Biologics, Inc, Promontory Therapeutics Inc., Palobiofarma SL, Regeneron Pharmaceuticals, Revolution Medicines, Inc., Cullinan Oncology, LLC, Iovance Biotherapeutics, Inc., Innate Pharma, and others |
| Key Non-small Cell Lung Cancer Therapies | M1774, C-TIL051, ACY-241 + Nivolumab, 18F-AraG, Nivolumab + Plinabulin, JIN-A02, FWD1509 MsOH, Osimertinib, BMS-813160, Sutetinib Maleate Capsule, Sotorasib and Tarloxotinib, RH324, AMG 794, Capmatinib, H002, VIC-1911, MYTX-011, ITIL-306, Adagrasib, DS-1062a, NEO-201 in combination with pembrolizumab, PT-112, PBF-1129, REGN2810, RMC-4630, CLN-081, LN-145, IPH5201 + durvalumab + standard chemotherapy, and others |
Scope of the Non-small Cell Lung Cancer Market Report
- Therapeutic Assessment: Non-small Cell Lung Cancer current marketed and emerging therapies
- Non-small Cell Lung Cancer Market Dynamics: Attribute Analysis of Emerging Non-small Cell Lung Cancer Drugs
- Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
- Unmet Needs, KOL’s views, Analyst’s views, Non-small Cell Lung Cancer Market Access and Reimbursement
Discover more about non-small cell lung cancer drugs in development @ Non-small Cell Lung Cancer Clinical Trials
Table of Contents
| 1. | Non-small Cell Lung Cancer Market Key Insights |
| 2. | Non-small Cell Lung Cancer Market Report Introduction |
| 3. | Non-small Cell Lung Cancer Market Overview at a Glance |
| 4. | Non-small Cell Lung Cancer Market Executive Summary |
| 5. | Disease Background and Overview |
| 6. | Non-small Cell Lung Cancer Treatment and Management |
| 7. | Non-small Cell Lung Cancer Epidemiology and Patient Population |
| 8. | Patient Journey |
| 9. | Non-small Cell Lung Cancer Marketed Drugs |
| 10. | Non-small Cell Lung Cancer Emerging Drugs |
| 11. | Seven Major Non-small Cell Lung Cancer Market Analysis |
| 12. | Non-small Cell Lung Cancer Market Outlook |
| 13. | Potential of Current and Emerging Therapies |
| 14. | KOL Views |
| 15. | Unmet Needs |
| 16. | SWOT Analysis |
| 17. | Appendix |
| 18. | DelveInsight Capabilities |
| 19. | Disclaimer |
| 20. | About DelveInsight |
Related Reports
Non-small Cell Lung Cancer Epidemiology Forecast
Non-small Cell Lung Cancer Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted non-small cell lung cancer epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Non-small Cell Lung Cancer Pipeline
Non-small Cell Lung Cancer Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key non-small cell lung cancer companies, including BridgeBio Pharma, Daiichi Sankyo, EMD Serono, Merck, BridgeBio Pharma, Abbvie, Pfizer, Eli Lilly and Company BioNTech SE, Shenzhen TargetRx, Taiho Pharmaceutical, Chong Kun Dang, Bristol Myers Squibb, Innovent Biologics, Xuanzhu Biopharmaceutical, Bayer, GeneScience Pharmaceuticals, InventisBio, Apollomics, Imugene, Ono Pharmaceutical, Pierre Fabre, Jiangsu Hengrui Medicine Co., Bristol-Myers Squibb, Surface Oncology, Inhibrx, Sinocelltech, Mirati Therapeutics, REVOLUTION Medicines, Yong Shun Technology Development, Iovance Biotherapeutics, Galecto Biotech, among others.
HER2-mutant Non-Small Cell Lung Cancer Pipeline
HER2-mutant Non-Small Cell Lung Cancer Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key HER2-mutant non-small cell lung cancer companies, including Dizal Pharmaceuticals, Puma Biotechnology, AstraZeneca, Jiangsu Hengrui Medicine, among others.
Small-cell Lung Cancer Pipeline
Small-cell Lung Cancer Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key small-cell lung cancer companies, including Ascentage Pharma, Merck & Co, AstraZeneca, Advenchen Laboratories, GlaxoSmithKline, Advanced Accelerator Applications, Trillium Therapeutics, Vernalis, Oncoceutics, NewBio Therapeutics, Wigen Biomedicine, Linton Pharm, Carrick Therapeutics, Xencor, Jiangsu HengRui Medicine, Aileron Therapeutics, Roche, Ipsen, Celgene, Lee's Pharmaceutical Limited, AbbVie, G1 Therapeutics, Chipscreen Biosciences, Luye Pharma Group, Shanghai Henlius Biotech, CSPC ZhongQi Pharmaceutical Technology, Impact Therapeutics, among others.
Small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key advanced small cell lung cancer companies, including Ascentage Pharma, Merck & Co, AstraZeneca, Advenchen Laboratories, Advanced Accelerator Applications, Trillium Therapeutics, Wigen Biomedicine, Linton Pharm, Carrick Therapeutics, among others.
Other Trending Reports
T-Cell Prolymphocytic Leukemia Market | Acral Lentiginous Melanoma Market | Malt Lymphoma Market | Primary Progressive Multiple Sclerosis Ppms Market | 3d Cardiac Mapping System Market | Adult Growth Hormone Deficiency Market | Angioedema Market | Pain Management Devices Market | Allergic Rhinoconjunctivitis Market | Multiple Myeloma Market | Blood Gas And Electrolyte Analyzers Market | Helicobacter Pylori Infection Market | Helicobacter Pylori Infections Market | Cardiac Amyloidosis Market | Cardiac Resynchronization Therapy Device Market | Cerebral Aneurysm Market | Anemia In Ckd Market | Capnography Device Market | Cutaneous T-cell Lymphoma Market | Chronic Hepatitis B Virus Market | Ventricular Hypertrophy Market | Parkinson’s Disease Market | Penicillinbinding Proteins Market | Critical Limb Ischemia Market | Hemophilia B Market | Cardiotoxicity Market | Xerostomia Market | Alopecia Market | Asmd Market | Hypothalamic Obesity Market | Chronic Cutaneous Ulcer Market | Chronic Insomnia Market | Adalimumab Biosimilar Market | Arbovirus Infection Market | Artificial Pancreas Device System Market | Dental Equipment Market | Gluten Sensitivity Market | Hypothyroidism Market | Inflammatory Bowel Disease Market | Mayus Kinase Jak Inhibitors Market | Mild Dry Eye Market | Mucopolysaccharidosis Market | Oncolytic Virus Cancer Therapy Market | Pyoderma Gangrenosum Market | Transdermal Drug Delivery Devices Market | Intrathecal Pumps Market | Hedgehog Pathway Inhibitors Market | Yellow Fever Market | Laryngeal Cancer Market | Female Infertility Market | Gender Dysphoria Market | Chronic Brain Damage Market | Spain Healthcare Outlook Market | Malignant Fibrous Histiocytoma Market | Bowen's Disease Market | Cartilage Diseases Market | Charcot-Marie-Tooth Disease Market | Cryptococcosis Market | Dental Lasers Market | Diabetes Market | Diverticulitis Market | Down Syndrome Market | Endocarditis Market | Extracorporeal Circulation System Market | Gastro Intestinal Bleeding Market | Gene Therapy for Ocular Rare Disease Market | Germ Cell Tumor Market | India Healthcare Outlook | Insulin Glargine Biosimilar Insight | Listeriosis Market | Liver Angiosarcoma Market | Lactose Intolerance Market | Meningococcal Meningitis Market | Radiodermatitis Market | Neuroendocrine Tumors Market | Intraocular Lymphoma Market | B-Cell Maturation Antigen Targeted Therapies Market | Atherosclerosis Market | Polycystic Ovarian Syndrome Market | Acute Myeloid Leukemia Market | Intraocular Lymphoma Market | Uveitis Market | Sepsis Market | Autoimmune Hepatitis | Primordial Dwarfism Market | Non-cystic Fibrosis Bronchiectasis Market | Microsatellite Stable Colorectal Cancer Market | Cystinuria Market | Deep Vein Thrombosis Market | Sialidosis Market | Blood Glucose Monitoring Systems Market | Chronic Rhinosinusitis Phenotype With Nasal | Polyps Market | Severe Hypoglycemia Market | Breast Pumps Market | Aids Dementia Market | Invasive Candidiasis Market | Severe Asthma | Fosmanogepix | Low Grade Glioma | Hand Eczema | Ulcerated Necrobiosis Lipoidica (uNL) | Molybdenum cofactor deficiency (MOCOD) - Type A | Sjogren's Disease | Anorexia Nervosa (AN) | Generalized Myasthenia Gravis | Seasonal Influenza | Underactive Bladder | Gastrointestinal Stromal Tumor (GIST) Epidemiology | Adrenocortical Carcinoma | Monkeypox Market | Pars Planitis Market | Patient Monitoring Devices Market | Typhoid Market | Zika Virus Market | Opioid Use Disorder Market
Related Healthcare Services
Healthcare Competitive Intelligence Services
Healthcare Asset Prioritization Services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Connect with us on LinkedIn|Facebook|Twitter
